Among the therapies currently approved for clinical use are the anti-CTLA-4 mAb ipilimumab (Yervoy®), which was the first immune checkpoint inhibitor to demonstrate an anti-cancer effect [18,19], and the anti-PD-1 mAb nivolumab (Opdivo®) [20]. The gene discussed is CTLA4; the disease is cancer.